Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome weighing the benefits and risks of prasugrel versus clopidogrel

Circulation: Cardiovascular Quality and Outcomes

Volumn 6, Issue 1, 2013, Pages 27-34

  Salisbury, Adam C ^a,b   Wang, Kaijun ^a   Cohen, David J ^a   Li, Yan ^a   Jones, Philip G ^a   Spertus, John A ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Cardiovascular Radiologic Imaging   (United States)

Author keywords

Acute coronary syndromes; Antiplatelet therapy; Individualized medicine; Percutaneous coronary intervention; Prediction

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; STROKE; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84873686350     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.112.965624     Document Type: Article

References (20)

1. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85.
2. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007;298:1209-1212.
3. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
4. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152:69-77.
5. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, Christianson TJ, Mullan RJ, Smith SA. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167:1076-1082.
6. Stalmeier PF. Adherence and decision AIDS: a model and a narrative review. Med Decis Making. 2011;31:121-129.
7. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166-1173.
8. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-635.
9. Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation. 2010;121:71-79.
10. Decker C, Arnold SV, Olabiyi O, Ahmad H, Gialde E, Luark J, Riggs L, DeJaynes T, Soto GE, Spertus JA. Implementing an innovative consent form: the PREDICT experience. Implement Sci. 2008;3:58.
11. Arnold SV, Decker C, Ahmad H, Olabiyi O, Mundluru S, Reid KJ, Soto GE, Gansert S, Spertus JA. Converting the informed consent from a perfunctory process to an evidence-based foundation for patient decision making. Circ Cardiovasc Qual Outcomes. 2008;1:21-28.
12. Soto GE, Jones PG, Spertus JA. Prism: Web-based framework for deploying predictive clinical models. Comput Cardiol. 2004;31: 193-196.
13. Shroyer AL, Coombs LP, Peterson ED, Eiken MC, DeLong ER, Chen A, Ferguson TB Jr., Grover FL, Edwards FH; Society of Thoracic Surgeons. The Society of Thoracic Surgeons: 30-day operative mortality and morbidity risk models. Ann Thorac Surg. 2003;75:1856-1864.
14. Online STS risk calculator. http://riskcalc.sts.org/STSWebRiskCalc273. Accessed February 6, 2012.
15. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel- Thrombolysis in Myocardial Infarction 38). Circulation. 2012;125:577-583.
16. Harrell FE. Regression Modeling Strategies. Secaucus, NJ: Springer-Verlag New York, Inc; 2006.
17. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley and Sons, Inc; 2000.
18. R Core DevelopmentTeam. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2006.
19. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the Twenty-First Century. Washington, DC: National Academy Press; 2001.
20. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18.